Universal Psychosocial Screening in Hospitalized Pediatric Patients: A Randomized Control Trial.

Clin Child Psychol PsychiatryMar 4, 2026 (epub)
Clinical ResearchPediatricsPsychiatry

Rebecca Liu, Alyssa Chong, Jeffrey N Bone et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated universal psychosocial screening with MyHEARTSMAP among 289 children admitted through an emergency department. Children assigned to screening completed the tool during their hospital stay, with results shared with clinicians; controls received standard care and completed it after discharge. Overall, psychosocial intervention was more frequent with screening, but the difference was not statistically significant (40.4% vs 32.9%; RR = 1.28, 95% CI [0.95, 1.73], p = .109). Among children with positive screens, intervention was significantly more frequent in the screening group (41.3% vs 25.1%; RR = 1.60, 95% CI [1.04, 2.46], p = .0318).

Key findings

  • Overall psychosocial intervention rates were 40.4% with screening and 32.9% with standard care; the difference was not statistically significant (RR = 1.28, 95% CI [0.95, 1.73], p = .109).
  • Among children with positive screens, intervention rates were 41.3% in the screening group and 25.1% in controls (RR = 1.60, 95% CI [1.04, 2.46], p = .0318).
  • Engagement with recommended services at 3 months post-discharge was overall modest.

Why it matters

Hospital admission may provide an opportunity to identify psychosocial concerns in children and connect them with support. The findings suggest that sharing screening results with clinicians may be particularly relevant for children who screen positive, although the overall intervention difference was uncertain. Modest follow-up engagement also indicates that identifying needs does not necessarily ensure families access recommended services.

What to keep in mind

The overall intervention difference was not statistically significant, and engagement with recommended services at 3 months was modest.

Source

Published in Clin Child Psychol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.